OncoSec enrolls 1st patient in immunotherapy clinical trial

OncoSec Medical has enrolled the first patient in a phase II clinical trial that uses ImmunoPulse IL-12, an immunotherapy platform, to treat patients with squamous cell carcinoma of the head and neck (HNSCC).

ImmunoPulse focuses on the delivery of DNA-based interleukin to cancerous tumor cells, using the patient's immune system to target the tumors. The key end points of the trial include the following:

  • Objective response evaluations using Response Evaluation Criteria in Solid Tumors and immune-related Response Criteria
  • Biomarker comparisons of pre- and post-tumor biopsies
  • Duration of treatment response
  • Overall survival and progression-free survival
  • Safety

"This study will address one of the great unmet medical needs in oncology today: the number of patients who do not respond to anti-PD-1 treatment," stated Mai H. Le, MD, chief medical officer of OncoSec, in a press release. "As we expand the application of ImmunoPulse IL-12 beyond cutaneous cancer indications, we anticipate that it will augment the antitumor immune response in HNSCC and increase the number of patients who will respond to anti-PD-1 therapy."

Page 1 of 7
Next Page